ABA. V. Bazarova

A. V. Bazarova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. V. Bazarova has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • STEREOTACTIC RADIOSURGERY USING GAMMA KNIFE FOR ITSENKO-CUSHING'S DISEASE

    by Bakirzhan M, Kozhemzharova M, Kuanyshbaeva G, Kamitbekova Z, Bazarova A, Astana Multidisciplinary City Hospital No. 1

    Stereotactic Gamma Knife radiosurgery is becoming the treatment of choice for patients with Cushing's disease that cannot be cured by surgery. The chances of 5-year remission are 65-75%, and control of tumor growth reaches more than 90%. However, the development of hypopituitarism (15% to 36%) is a common side effect, and severe neurological complications are rare. Relapse of the disease occurs in 16-18% of patients, but the reasons for this are unclear. Stereotactic Gamma Knife radiosurgery is effective as second line therapy in surgically untreated patients. The purpose of the study is to evaluate the effectiveness of stereotactic gamma knife radiosurgery as an adjuvant treatment for Cushing's disease, and also to consider possible complications and undesirable effects associated with the use of Stereotactic Gamma Knife radiosurgery in the treatment of Cushing’s disease. The authors analyzed the published results of international, multicenter and retrospective cohort studies on the use of Stereotactic Gamma Knife radiosurgery in patients with. According to published data, the average time to achieve remission after Stereotactic Gamma Knife radiosurgery in patients with Cushing’s disease was 16-17 months, while remission was maintained for 10 years in 60-80% of patients. Tumor growth control was achieved in 95% of cases. Our article suggests that radiosurgery is a safe and well-tolerated procedure and can provide long-term control of hypercortisolism in the majority of patients with Cushing’s disease. However, given the likelihood of relapse after initial normalization of cortisol levels and the manifestation of hypopituitarism, long-term endocrine monitoring after radiosurgery is necessary. Ultimately, radiosurgery may be considered a reasonable primary treatment option for carefully selected patients who cannot have another treatment.

  • Open Access

    The effect of a structured non-pharmacological treatment of type 2 diabetes on glycated hemoglobin and body weight: a randomized controlled trial

    by V. V. Li, Ye. D. Dalenov, L. K. Dzeranova, S. V. Kim, A. V. Bazarova, S. K. Tarjibayeva, N. V. Slivkina, I. S. Kim

    BACKGROUND: Non-pharmacological treatments are an integral part of the treatment of all patients with type 2 diabetes (T2D). However, due to many factors, doctors and patients themselves tend to underestimate or completely neglect such effective methods in managing the course of the disease. Despite the high level of evidence of the effectiveness of this type of treatment for T2D, every year scientists around the world continue to actively study the effect of various non-drug methods on the course of the disease.AIM: To study the effect of a 24-week structured non-pharmacological treatment program on glycated hemoglobin reduction and weight loss in middle-aged patients with compensated T2D taking metformin.MATERIALS AND METHODS: A two-group, randomized, parallel-group, blinded trial was designed. Patients with an established diagnosis of T2D in the stage of compensation (HbA1c ≤7%), aged 45–59 years, taking metformin, were randomized to receive either standard non-pharmacological treatment of diabetes according to clinical protocol of T2D treatment in Kazakhstan, or an intensive course of non-pharmacological treatment according to a structured program developed by researchers. The duration of the intervention was 24 weeks. Primary outcomes were glycated hemoglobin, body weight. Secondary outcomes: blood pressure, waist circumference, insulin resistance index (HOMA-IR), lipid profile: total cholesterol, high and low density lipoproteins, triglycerides. The outcomes of the participants in both groups were assessed at baseline, 12 and 24 weeks after randomization. The study is registered with ClinicalTrials.gov NCT04632823.RESULTS: The study included 200 patients, 67 patients completed the study: intervention group n=33, control group n=34. After 24 weeks of observation, patients in the intervention group showed a significant decrease in HbA1c from 6.34% to 6.22%, p1c remained the same at 6.5% (p=0.703). Patients in both groups significantly reduced body weight, however, the decrease in the intervention group was more significant: by 6.7% of the initial level, while in the control group, only 1.1%. LDL, triglycerides, cholesterol level, HOMA-IR 2, and diastolic blood pressure did not decline significantly in the control group. All biochemical characteristics except triglycerides and LDL decreased significantly in the intervention group.CONCLUSION: The use of a structured program of non-pharmacological treatment of type 2 diabetes mellitus among compensated (HbA1c ≤7%) middle-aged patients who took metformin significantly reduced body weight and glycated hemoglobin in 24 weeks.


  • Клиническое значение результатов исследования DAPA HF (Dapagliflozin and prevention of adverse-outcomes in heart failure) для пациентов и врачей. Консенсус совета Экспертов

    by Shymkent Turkestan Regional Cardiology Center, Gulmira Alipova, Anna Bazarova, Nazira Bazarova, Karaganda Polyclinic No 3, Rimma Bazarbekova, Gulnara Bedelbaeva, Irina Guseva, Aktobe Polyclinic No 2, Gulnara Junusbekova, et al.

    The article presents the results of the DAPA-HF study - evaluating the efficacy of dapagliflozin, used at a dose of 10 mg once a day, in addition to the standard treatment for patients with chronic heart failure with reduced left ventricular ejection fraction, compared to placebo. An analysis of current clinical recommendations related to this issue was carried out, the results of recent clinical studies and metaanalyses conducted were highlighted. Based on the results of the study, the need is postulated to optimize drug therapy of this category to patients with persistent symptoms of heart failure, despite standard therapy, with the addition of dapagliflozin to reduce the risk of cardiovascular death and hospitalizations for heart failure, improve the course of the disease. Keywords: chronic heart failure, dapagliflozin, low ejection fraction, effects of type 2 sodium-glucose co transporter inhibitors, diabetes mellitus.